Seer, Inc.

Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population health Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population health

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Gulyani. *** September 4, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Meeta Gulyani Dear Ms. Gulyani, As you know, we are significant stockholders of Seer, Inc. (“Seer” or the “Company”), collectively owning approximately 7.7% of the Company's.

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today issued the following open letter to the Company's Board of Directors. *** August 13, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Board of Directors Dear Members of the Board of Directors (the “Board”), Bradley L. Radoff and Michael Torok (together with certain of their affiliat.

Seer NASDAQ: SEER reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter, as the proteomics company cited continued pressure on academic and government funding and longer sales cycles among some commercial customers.